Nishiyama Akira, Seth Dale M, Navar L Gabriel
Department of Pharmacology, Kagawa Medical University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
J Hypertens. 2003 Oct;21(10):1897-903. doi: 10.1097/00004872-200310000-00017.
Angiotensin II (Ang II)-dependent hypertension is associated with augmented intrarenal concentrations of Ang II; however, the distribution of the increased intrarenal Ang II has not been fully established.
To determine the changes in renal interstitial fluid Ang II concentrations in Ang II-induced hypertension and the consequences of treatment with an angiotensin II type 1 (AT1) receptor blocker.
Rats were selected to receive vehicle (5% acetic acid subcutaneously; n = 6), Ang II (80 ng/min subcutaneously, via osmotic minipump; n = 7) or Ang II plus an AT1 receptor antagonist, candesartan cilexetil (10 mg/kg per day, in drinking water; n = 6) for 13-14 days, at which time, experiments were performed on anesthetized rats. Microdialysis probes were implanted in the renal cortex and were perfused at 2 microl/min. The effluent dialysate concentrations of Ang I and Ang II were measured by radioimmunoassay and reported values were corrected for the equilibrium rates at this perfusion rate.
Ang II-infused rats developed greater mean arterial pressures (155 +/- 7 mmHg) than vehicle-infused rats (108 +/- 3 mmHg). Ang II-infused rats showed greater plasma (181 +/- 30 fmol/ml) and kidney (330 +/- 38 fmol/g) Ang II concentrations than vehicle-infused rats (98 +/- 14 fmol/ml and 157 +/- 22 fmol/g, respectively). Renal interstitial fluid Ang II concentrations were much greater than plasma concentrations, averaging 5.74 +/- 0.26 pmol/ml in Ang II-infused rats - significantly greater than those in vehicle-infused rats (2.86 +/- 0.23 pmol/ml). Candesartan treatment prevented the hypertension (87 +/- 3 mmHg) and led to increased plasma Ang II concentrations (441 +/- 27 fmol/ml), but prevented increases in kidney (120 +/- 15 fmol/g) and renal interstitial fluid (2.15 +/- 0.12 pmol/ml) Ang II concentrations.
These data indicate that Ang II-infused rats develop increased renal interstitial fluid concentrations of Ang II, which may contribute to the increased vascular resistance and reduced sodium excretion. Furthermore, the augmentation of renal interstitial fluid Ang II is the result of an AT1 receptor-mediated process and can be dissociated from the plasma concentrations.
血管紧张素II(Ang II)依赖性高血压与肾内Ang II浓度升高有关;然而,肾内Ang II升高的分布尚未完全明确。
确定Ang II诱导的高血压大鼠肾间质液中Ang II浓度的变化以及用1型血管紧张素II(AT1)受体阻滞剂治疗的后果。
选取大鼠,分别给予载体(皮下注射5%醋酸;n = 6)、Ang II(通过渗透微型泵皮下注射80 ng/分钟;n = 7)或Ang II加AT1受体拮抗剂坎地沙坦酯(每天10 mg/kg,饮水给药;n = 6),持续13 - 14天,此时对麻醉大鼠进行实验。将微透析探针植入肾皮质,以2微升/分钟的速度进行灌注。通过放射免疫分析法测量流出透析液中Ang I和Ang II的浓度,并根据该灌注速度下的平衡率对报告值进行校正。
输注Ang II的大鼠平均动脉压(155±7 mmHg)高于输注载体的大鼠(108±3 mmHg)。输注Ang II的大鼠血浆(181±30 fmol/ml)和肾脏(330±38 fmol/g)中Ang II浓度高于输注载体的大鼠(分别为98±14 fmol/ml和157±22 fmol/g)。肾间质液中Ang II浓度远高于血浆浓度,输注Ang II的大鼠平均为5.74±0.26 pmol/ml,显著高于输注载体的大鼠(2.86±0.23 pmol/ml)。坎地沙坦治疗可预防高血压(87±3 mmHg),并导致血浆Ang II浓度升高(441±27 fmol/ml),但可预防肾脏(120±15 fmol/g)和肾间质液(2.15±0.